|
1
|
Hsieh TY, Chang KP, Lee SS, Chang CH, Lai
CH, Wu YC, Huang SH, Lai CS and Lin SD: Free flap reconstruction in
patients with advanced oral squamous cell carcinoma: Analysis of
patient survival and cancer recurrence. Microsurgery. 32:598–604.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. Feb 4–2021.(Epub ahead
of print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ministry of Health Welfare, . The cause of
death in Taiwan in 2018. https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=13498
|
|
4
|
Rivera C and Venegas B: Histological and
molecular aspects of oral squamous cell carcinoma (Review). Oncol
Lett. 8:7–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liao CT, Wang HM, Ng SH, Yen TC, Lee LY,
Hsueh C, Wei FC, Chen IH, Kang CJ, Huang SF and Chang JT: Good
tumor control and survivals of squamous cell carcinoma of buccal
mucosa treated with radical surgery with or without neck dissection
in Taiwan. Oral Oncol. 42:800–809. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eich HT, Löschcke M, Scheer M, Kocher M,
Bongartz R, Wacker S, Zöller JE and Müller RP: Neoadjuvant
radiochemotherapy and radical resection for advanced squamous cell
carcinoma of the oral cavity. Outcome of 134 patients. Strahlenther
Onkol. 184:23–29. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kreppel M, Drebber U, Eich HT, Dreiseidler
T, Zöller JE, Müller RP and Scheer M: Combined-modality treatment
in advanced oral squamous cell carcinoma: Primary surgery followed
by adjuvant concomitant radiochemotherapy. Strahlenther Onkol.
187:555–560. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fan KH, Wang HM, Kang CJ, Lee LY, Huang
SF, Lin CY, Chen EY, Chen IH, Liao CT and Chang JT: Treatment
results of postoperative radiotherapy on squamous cell carcinoma of
the oral cavity: Coexistence of multiple minor risk factors results
in higher recurrence rates. Int J Radiat Oncol Biol Phys.
77:1024–1029. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Woolgar JA, Rogers S, West CR, Errington
RD, Brown JS and Vaughan ED: Survival and patterns of recurrence in
200 oral cancer patients treated by radical surgery and neck
dissection. Oral Oncol. 35:257–265. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu CH, Chen HJ, Wang PC, Chen HS and
Chang YL: Patterns of recurrence and second primary tumors in oral
squamous cell carcinoma treated with surgery alone. Kaohsiung J Med
Sci. 29:554–559. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang B, Zhang S, Yue K and Wang XD: The
recurrence and survival of oral squamous cell carcinoma: A report
of 275 cases. Chin J Cancer. 32:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bernier J, Domenge C, Ozsahin M,
Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P,
Rolland F, Bolla M, et al: Postoperative irradiation with or
without concomitant chemotherapy for locally advanced head and neck
cancer. N Engl J Med. 350:1945–1952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cooper JS, Pajak TF, Forastiere AA, Jacobs
J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et
al: Postoperative concurrent radiotherapy and chemotherapy for
high-risk squamous-cell carcinoma of the head and neck. N Engl J
Med. 350:1937–1944. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fan S, Tang QL, Lin YJ, Chen WL, Li JS,
Huang ZQ, Yang ZH, Wang YY, Zhang DM, Wang HJ, et al: A review of
clinical and histological parameters associated with contralateral
neck metastases in oral squamous cell carcinoma. Int J Oral Sci.
3:180–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pignon JP, le Maître A, Maillard E and
Bourhis J; MACH-NC Collaborative Group, : Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Winquist E, Agbassi C, Meyers BM, Yoo J
and Chan KKW; Head and Neck Disease Site Group, : Systemic therapy
in the curative treatment of head and neck squamous cell cancer: A
systematic review. J Otolaryngol Head Neck Surg. 46:292017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dabholkar M, Vionnet J, Bostick-Bruton F,
Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian
cancer tissue correlate with response to platinum-based
chemotherapy. J Clin Invest. 94:703–708. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Murray D and Rosenberg E: The importance
of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance
does not appear to derive from its participation in the nucleotide
excision repair pathway. Mutat Res. 364:217–226. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Manic S, Gatti L, Carenini N, Fumagalli G,
Zunino F and Perego P: Mechanisms controlling sensitivity to
platinum complexes: Role of p53 and DNA mismatch repair. Curr
Cancer Drug Targets. 3:21–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sancar A: DNA excision repair. Annu Rev
Biochem. 65:43–81. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Petit C and Sancar A: Nucleotide excision
repair: From E. coli to man. Biochimie. 81:15–25. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al: DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Felip E and Rosell R: Testing for excision
repair cross-complementing 1 in patients with non-small-cell lung
cancer for chemotherapy response. Expert Rev Mol Diagn. 7:261–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Olaussen KA, Mountzios G and Soria JC:
ERCC1 as a risk stratifier in platinum-based chemotherapy for
nonsmall-cell lung cancer. Curr Opin Pulm Med. 13:284–289. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: Gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
26
|
Weaver DA, Crawford EL, Warner KA,
Elkhairi F, Khuder SA and Willey JC: ABCC5, ERCC2, XPA and XRCC1
transcript abundance levels correlate with cisplatin
chemoresistance in non-small cell lung cancer cell lines. Mol
Cancer. 4:182005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang MY, Tsai HL, Lin CH, Huang CW, Ma
CJ, Huang CM, Chai CY and Wang JY: Predictive value of ERCC1,
ERCC2, and XRCC1 overexpression for stage III colorectal cancer
patients receiving FOLFOX-4 adjuvant chemotherapy. J Surg Oncol.
108:457–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT
and Chen YJ: High ERCC1 expression predicts cisplatin-based
chemotherapy resistance and poor outcome in unresectable squamous
cell carcinoma of head and neck in a betel-chewing area. J Transl
Med. 9:312011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Caldecott KW: XRCC1 and DNA strand break
repair. DNA Repair (Amst). 2:955–969. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nix P, Greenman J, Stafford N and Cawkwell
L: Expression of XRCC 1 and ERCC 1 proteins in radioresistant and
radiosensitive laryngeal cancer. Cancer Ther. 2:47–53. 2004.
|
|
31
|
Estilo CL, O-charoenrat P, Talbot S, Socci
ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y,
Boyle JO, et al: Oral tongue cancer gene expression profiling:
Identification of novel potential prognosticators by
oligonucleotide microarray analysis. BMC Cancer. 9:112009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Peng CH, Liao CT, Peng SC, Chen YJ, Cheng
AJ, Juang JL, Tsai CY, Chen TC, Chuang YJ, Tang CY, et al: A novel
molecular signature identified by systems genetics approach
predicts prognosis in oral squamous cell carcinoma. PLoS One.
6:e234522011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cromer A, Carles A, Millon R, Ganguli G,
Chalmel F, Lemaire F, Young J, Dembélé D, Thibault C, Muller D, et
al: Identification of genes associated with tumorigenesis and
metastatic potential of hypopharyngeal cancer by microarray
analysis. Oncogene. 23:2484–2498. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ginos MA, Page GP, Michalowicz BS, Patel
KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL and Gaffney PM:
Identification of a gene expression signature associated with
recurrent disease in squamous cell carcinoma of the head and neck.
Cancer Res. 64:55–63. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Verschuur HP, Irish JC, O'Sullivan B, Goh
C, Gullane PJ and Pintilie M: A matched control study of treatment
outcome in young patients with squamous cell carcinoma of the head
and neck. Laryngoscope. 109:249–258. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boccard SG, Marand SV, Geraci S, Pycroft
L, Berger FR and Pelletier LA: Inhibition of DNA-repair genes Ercc1
and Mgmt enhances temozolomide efficacy in gliomas treatment: A
pre-clinical study. Oncotarget. 6:29456–29468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC and
Zhang L: Expression of ERCC1 predicts clinical outcome in
locoregionally advanced nasopharyngeal carcinoma treated with
cisplatin-based induction chemotherapy. Oral Oncol. 48:964–968.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gao Y and Liu D: The roles of excision
repair cross-complementation group1 in objective response after
cisplatin-based concurrent chemoradiotherapy and survival in head
and neck cancers: A systematic review and meta-analysis. Oral
Oncol. 51:570–577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bauman JE, Austin MC, Schmidt R, Kurland
BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S
and Martins RG: ERCC1 is a prognostic biomarker in locally advanced
head and neck cancer: Results from a randomised, phase II trial. Br
J Cancer. 109:2096–2105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
An HJ, Jo H, Jung CK, Kang JH, Kim MS, Sun
DI, Cho KJ, Cho JH, Won HS, Sun S and Ko YH: Prognostic implication
of ERCC1 protein expression in resected oropharynx and oral cavity
cancer. Pathol Res Pract. 213:949–955. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang L, Wei W, Zhou L, Wang J and Hu G:
High/positive expression of ERCC1 predicts poor treatment response
and survival prognosis in nasopharyngeal carcinoma: A systematic
meta-analysis from 21 studies. Medicine (Baltimore). 98:e156412019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang Y, Wang Y, Wu J and Li LJ: XRCC1
Arg194Trp polymorphism is associated with oral cancer risk:
Evidence from a meta-analysis. Tumour Biol. 34:2321–2327. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang CH, Lin YD, Yen CY, Chuang LY and
Chang HW: A systematic gene-gene and gene-environment interaction
analysis of DNA repair genes XRCC1, XRCC2, XRCC3, XRCC4, and oral
cancer risk. Omics. 19:238–247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Avci H, Ergen A, Bireller ES, Ertugrul B
and Cakmakoglu B: A strong relationship between oral squamous cell
carcinoma and DNA repair genes. Biochem Genet. 55:378–386. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang E, Cui Z, Xu Z, Duan W, Huang S, Tan
X, Yin Z, Sun C and Lu L: Association between polymorphisms in
ERCC2 gene and oral cancer risk: Evidence from a meta-analysis. BMC
Cancer. 13:5942013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vaezi A, Feldman CH and Niedernhofer LJ:
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.
Pharmgenomics Pers Med. 4:47–63. 2011.PubMed/NCBI
|
|
48
|
Zafeer M, Mahjabeen I and Kayani MA:
Increased expression of ERCC2 gene in head and neck cancer is
associated with aggressive tumors: A systematic review and
case-control study. Int J Biol Markers. 31:e17–e25. 2016.
View Article : Google Scholar
|
|
49
|
Du P, Wang Y, Chen L, Gan Y and Wu Q: High
ERCC1 expression is associated with platinum-resistance, but not
survival in patients with epithelial ovarian cancer. Oncol Lett.
12:857–862. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu J, Zhang L, Mao P, Jiang G, Liu L,
Wang J, Yang W, Owusu L and Li W: Functional characterization of a
novel transcript of ERCC1 in chemotherapy resistance of ovarian
cancer. Oncotarget. 8:85759–85771. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gossage L and Madhusudan S: Current status
of excision repair cross complementing-group 1 (ERCC1) in cancer.
Cancer Treat Rev. 33:565–577. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lai JI, Tzeng CH, Chen PM, Lin JK, Lin TC,
Chen WS, Jiang JK, Wang HS and Wang WS: Very low prevalence of XPD
K751Q polymorphism and its association with XPD expression and
outcomes of FOLFOX-4 treatment in Asian patients with colorectal
carcinoma. Cancer Sci. 100:1261–1266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Curtin NJ: DNA repair dysregulation from
cancer driver to therapeutic target. Nat Rev Cancer. 12:801–817.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Schulz A, Meyer F, Dubrovska A and
Borgmann K: Cancer stem cells and radioresistance: DNA repair and
beyond. Cancers (Basel). 11:8622019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Huang RX and Zhou PK: DNA damage response
signaling pathways and targets for radiotherapy sensitization in
cancer. Signal Transduct Target Ther. 5:602020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Johnson N: Tobacco use and oral cancer: A
global perspective. J Dent Educ. 65:328–339. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM
and Tsai CC: Betel quid chewing, cigarette smoking and alcohol
consumption related to oral cancer in Taiwan. J Oral Pathol Med.
24:450–453. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Abrahão R, Anantharaman D, Gaborieau V,
Abedi-Ardekani B, Lagiou P, Lagiou A, Ahrens W, Holcatova I, Betka
J, Merletti F, et al: The influence of smoking, age and stage at
diagnosis on the survival after larynx, hypopharynx and oral cavity
cancers in Europe: The ARCAGE study. Int J Cancer. 143:32–44. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cao W, Liu Z, Gokavarapu S, Chen Y, Yang R
and Ji T: Reformed smokers have survival benefits after head and
neck cancer. Br J Oral Maxillofac Surg. 54:818–825. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Colares N, Souza Rodrigues DF, Freitas MO,
Dantas TS, Cunha MDPSS, Sousa FB and Barros Silva PG: Smoking
history decreases survival in patients with squamous cell carcinoma
of the mouth: A retrospective study with 15 years of follow-up.
Asian Pac J Cancer Prev. 20:1781–1787. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kawakita D, Hosono S, Ito H, Oze I,
Watanabe M, Hanai N, Hasegawa Y, Tajima K, Murakami S, Tanaka H and
Matsuo K: Impact of smoking status on clinical outcome in oral
cavity cancer patients. Oral Oncol. 48:186–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lee SU, Moon SH, Choi SW, Cho KH, Park JY,
Jung YS, Ryu J, Ryu CH, Yun T, Kim TH, et al: Prognostic
significance of smoking and alcohol history in young age oral
cavity cancer. Oral Dis. 26:1440–1448. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Koshiaris C, Aveyard P, Oke J, Ryan R,
Szatkowski L, Stevens R and Farley A: Smoking cessation and
survival in lung, upper aero-digestive tract and bladder cancer:
Cohort study. Br J Cancer. 117:1224–1232. 2017. View Article : Google Scholar : PubMed/NCBI
|
